GlobeNewswire Inc.··Rosen Law FirmUltragenyx Investors Face April Deadline in Securities Litigation Over Setrusumab Claims
Ultragenyx faces securities lawsuit alleging misleading claims about setrusumab's efficacy. Investors must act by April 6, 2026 deadline to join class action.
RAREsecurities fraudclass action lawsuit